In patients, high TIGIT/DNAM-1 ratio on tumor-infiltrating Tregs has been found to be associated with poor clinical outcomes in melanoma following anti-PD-1 or anti-CTLA-4 therapies (8). Here, CD226 is linked to neoplasm.